FDA clears Immucor's new blood screening system
This article was originally published in Clinica
Immucor's fourth-generation automated blood testing instrument, Neo, has received 510(k) clearance from the US FDA. The device is designed to help high-throughput blood banks and laboratories increase productivity, performance and flexibility, Norcross, Georgia-based Immucor claims. Neo can process up to 224 samples at once, and operators can add samples at any time. Its test menu includes ABO/Rh blood typing, and antigen and antibody screening. The firm already markets other blood screening systems, including the Galileo and Galileo Echo.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.